Glenmark Pharmaceuticals has informed about media release titled, 'Glenmark Pharmaceuticals Announces Oral Presentation of New Data on GBR 830, an Investigational, Anti-OX40 Monoclonal Antibody, at the International Investigative Dermatology Meeting'.
The above information is a part of company’s filings submitted to BSE.